Singapore markets closed

SpringWorks Therapeutics, Inc. (SWTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
68.53-2.33 (-3.29%)
As of 11:31AM EST. Market open.

SpringWorks Therapeutics, Inc.

100 Washington Boulevard
Stamford, CT 06902
United States
203 883 9490

Full-time employees142

Key executives

NameTitlePayExercisedYear born
Mr. Saqib IslamCEO & Director946.31kN/A1970
Mr. Francis I. Perier Jr., M.B.A.Chief Financial Officer648.96kN/A1960
Dr. Badreddin Edris Ph.D.Chief Operating Officer655.2kN/A1987
Mr. Herschel S. Weinstein J.D.Gen. Counsel & Sec.568.64kN/A1956
Mr. Daniel PichlChief People Officer428.51kN/A1983
Dr. L. Mary Smith PH.D.Chief Devel. Officer655.2kN/A1967
Mr. Michael P. NofiChief Accounting OfficerN/AN/A1971
Ms. Kim DiamondVP of Communications & Investor RelationsN/AN/AN/A
Mr. Bhavesh AsharChief Commercial OfficerN/AN/A1966
Dr. Michael F. Burgess M.D., MBChB, Ph.D.Head of R&DN/AN/A1963
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase 3 clinical trials for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas; Nirogacestat + belantamab mafodotin -blmf, which is in Phase Ib clinical trial for the treatment of relapsed or refractory multiple myeloma (RRMM); and Nirogacestat + ALLO-715 that is in Phase 1 clinical trial for the treatment of RRMM. In addition, it is developing Nirogacestat + teclistamab, which is in clinical stage that targets BCMA and CD3; Nirogacestat + elranatamab; Nirogacestat + PBCAR269A, which is in Phase 1/2a clinical trial for allogeneic BCMA CAR T cell therapy; Mirdametinib that is in Phase 1/2a clinical trial for the treatment of NF1-PN; Mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; collaboration agreement with Ab Magnitude Ventures Group, LLC and Ab Magnitude Fund, LP; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology; and clinical trial collaboration agreement with Seagen Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.

Corporate governance

SpringWorks Therapeutics, Inc.’s ISS governance QualityScore as of 26 September 2021 is 10. The pillar scores are Audit: 7; Board: 10; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.